Quantcast

Latest Telik Inc. Stories

2011-02-09 03:25:00

PALO ALTO, Calif., Feb. 9, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 13th Annual BIO CEO & Investor Conference in New York City on Tuesday, February 15 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time), in the Waldorf-Astoria Hotel's Conrad Suite. A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. The archived broadcast of the...

2010-11-10 13:44:00

PALO ALTO, Calif., Nov. 10, 2010 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today it will report data from the Phase 2 randomized multicenter study of Telintra® (ezatiostat HCl) tablets in the treatment of patients with Myelodysplastic Syndrome at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL. Details of the presentation are as follows: Abstract #2910 -Myelodysplastic Syndromes: Poster II; Sunday, December 5,...

2010-11-03 15:05:00

PALO ALTO, Calif., Nov. 3, 2010 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $4.7 million, or $0.09 per share, for the third quarter ended September 30, 2010, compared with a net loss of $6.1 million, or $0.11 per share, for the comparable period in 2009. For the quarter ended September 30, 2010, total operating costs and expenses were $4.7 million, compared with $6.2 million in the 2009 third quarter. Operating expenses in the 2010 third quarter...

2010-11-02 18:27:00

PALO ALTO, Calif., Nov. 2, 2010 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) a clinical stage drug development company focused on developing drugs to treat cancer, announced that it has been awarded grants totaling $1,222,396 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP). The grants are intended to advance five of Telik's ongoing therapeutic drug development programs including the company's most advanced investigational drug candidate,...

2010-10-26 13:57:00

PALO ALTO, Calif., Oct. 26 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today that Telintra (Ezatiostat HCl), the company's lead therapeutic product candidate, has been selected by Windhover Information and its advisors as one of "The Top 10 Most Interesting Oncology Projects to Watch." Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries. The company has been invited to present at...

2010-08-06 15:05:00

PALO ALTO, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $4.9 million, or $0.09 per share, for the second quarter ended June 30, 2010, compared with a net loss of $5.7 million, or $0.11 per share, for the comparable period in 2009. For the quarter ended June 30, 2010, total operating costs and expenses were $5.0 million, compared with $6.3 million in the 2009 second quarter. Operating expenses in the 2010 second quarter included...

2010-07-12 13:25:00

PALO ALTO, Calif., July 12 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and...

2010-06-21 13:33:00

PALO ALTO, Calif., June 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of a case report by Quddus et al., Oral Ezatiostat HCl (Telintra) and Myelodysplastic Syndrome: A case report of sustained hematologic response following an abbreviated exposure. Journal of Hematology & Oncology 2010, 3:16. This case report describes a patient who experienced a sustained hematologic response in all three blood cell lines continuing for over a year, after an...

2010-06-08 08:00:00

PALO ALTO, Calif., June 8 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced positive results from a Phase 2 multicenter trial of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with an International Prognostic System Score (IPSS) low to intermediate-1 risk myelodysplastic syndrome (MDS). The primary objective of the study was to determine the Hematologic Improvement (HI) rate according to the International Working Group criteria (IWG, 2006). Since MDS...

2010-06-02 15:05:00

PALO ALTO, Calif., June 2 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that company management will provide corporate overviews at the following investment conferences: Jefferies 2010 Global Life Sciences Conference, New York; Wednesday, June 9, 2010 at 1:30 p.m. EDT (10:30 a.m. PDT) 9th Annual Needham Healthcare Conference, New York; Thursday, June 10, 2010 at 2:00 p.m. EDT (11:00 a.m. PDT) A live and archived webcast of the Needham presentation will be...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related